Multicenter phase II study of adding bi-weekly cetuximab to oral S-1 therapy in advanced colorectal cancer who have failed prior oxaliplatin and irinotecan-based therapies
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2016
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 16 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2011 Planned End Date added to 1 Sep 2016 as reported by University Hospital Medical Information Network - Japan.
- 13 Oct 2011 New trial record